Mefloquine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Malaria Initially, 15 mg/kg followed by 10 mg/kg after 6-24 hr. Malaria prophylaxis 250 mg/wk taken 1-3 wk before exposure and continuing for 4 wk after leaving the malarious area.
Administration
Should be taken with food. Best taken w/ meals & a full glass of water.
Contraindications
Hypersensitivity to related compounds (e.g. quinine and quinidine); history of blackwater fever;, prophylactic use in patients w/ history of psychiatric (including depression) or convulsive disorders; retreatment w/ mefloquine. Severe hepatic impairment. Concomitant use w/ halofantrine.
Special Precautions
Patients w/ epilepsy, acute anxiety, restlessness or confusion, cardiac conduction disorders. Renal impairment. Pregnancy and lactation. Patient Counselling May impair ability to drive and operate machineries. Monitoring Parameters Periodic evaluation of liver function and ophthalmologic examinations (long-term prophylaxis). Neuropsychiatric symptoms; atypical behaviour (suicidal ideation and behaviour) during and after therapy.
Adverse Reactions
Diarrhoea, nausea, vomiting, pruritus, rash, abdominal pain, anorexia, dizziness or vertigo, loss of balance, somnolence and sleep disorders (e.g. insomnia and abnormal dreams). Neuropsychiatric disturbances including motor and sensory neuropathies, ataxia, tremor, visual disorders (e.g. retinal degeneration or optic neuropathy), tinnitus and hearing impairment, convulsions, anxiety, depression, hallucinations, confusion, panic attacks, emotional instability, aggression and agitation, and acute psychosis, suicidal ideation; hair loss, myalgia. Decreased haematocrit and increased transaminase value; thrombocytopenia and leucopenia.
Drug Interactions
Increased risk of ECG abnormalities w/ quinine or chloroquine, antihistamines, TCAs and phenothiazines. May increase risk of seizure w/ quinidine or quinine. Concomitant use w/ valproic acid, phenobarbital, carbamazepine and phenytoin may cause loss of seizure control and lower plasma levels of anticonvulsants. Increased risk of QT prolongation and arrhythmia w/ ketoconazole. Concomitant use w/ digoxin, Ca-channel blockers, antiarrhythmics and β-blockers may increase the risk of cardiotoxicity. Increased risk of ventricular arrhythmias w/ amiodarone. Concomitant use w/ TCAs, SSRIs, buprion, antipsychotic, tramadol may increase the risk of convulsions. Increased plasma levels w/ metoclopromide. May compromise adequate immunisation by live typhoid vaccine. Vaccinations w/ attenuated live bacteria should be completed at least 3 days prior the 1st dose of mefloquine.
CIMS Class
ATC Classification
P01BC02 - mefloquine ; Belongs to the class of methanolquinoline antimalarials.
Disclaimer: This information is independently developed by CIMS based on mefloquine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in